Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORDAS, EMILY ANN | 1 | 50.6% | +58.5% |
| PETERS, ALEC JON | 1 | 68.6% | +61.7% |
| HOLTZMAN, KATHERINE ANN | 1 | 64.5% | +57.9% |
| BRISTOL, LYNN ANNE | 1 | 63.7% | +39.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773422 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CORDAS, EMILY ANN | 70d overdue |
| 17507456 | CONDITIONING METHODS FOR GENE THERAPY | PETERS, ALEC JON | 52d overdue |
| 17368815 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | HOLTZMAN, KATHERINE ANN | 36d overdue |
| 16863948 | FC SILENCED ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ADCS) | BRISTOL, LYNN ANNE | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1641 | 1 |
| 1646 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17773422 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CORDAS, EMILY ANN | 1632 | §103 | Non-Final OA | 70d overdue | Pending | Apr 29, 2022 |
| 17507456 | CONDITIONING METHODS FOR GENE THERAPY | PETERS, ALEC JON | 1641 | Other | Final Rejection | 52d overdue | Pending | Oct 21, 2021 |
| 17368815 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | HOLTZMAN, KATHERINE ANN | 1646 | §103 | Final Rejection | 36d overdue | Pending | Jul 06, 2021 |
| 16863948 | FC SILENCED ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ADCS) | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 2d overdue | Pending | Apr 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial